Ignite Creation Date:
2024-05-06 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05238116
Status:
RECRUITING
Last Update Posted:
2024-06-20
First Post:
2022-02-03
Brief Title:
Safety and Efficacy of PC945 Opelconazole in Combination With Other Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis OPERA-T Study
Sponsor:
Pulmocide Ltd
Organization:
Pulmocide Ltd
Study Overview
Official Title:
A Double-blind Randomized Placebo-controlled Study to Assess the Safety and Efficacy of Nebulized PC945 When Added to Systemic Antifungal Therapy for the Treatment of Refractory Invasive Pulmonary Aspergillosis OPERA-T Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the safety and efficacy of nebulized PC945 in combination with systemic antifungal therapy for the treatment of refractory IPA
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2024-511281-36 | REGISTRY | EU CT Number | None |
| 2021-004554-32 | EUDRACT_NUMBER | None | None |